Adiposis; Heart, Coronary Artery Disease (CAD) (E.G., Angina, Myocardial Infarction, and Atherosclerotic Heart Disease (ASHD)), Obesity
Conditions
Keywords
Coronary artery disease, Adipokines, Obesity, Diabetes mellitus
Brief summary
The purpose of this study is to investigate the efficacy and mechanism of Adipokines Cardiac Protection in Obese Patients With coronary artery disease (CAD).
Detailed description
Adipokines (or adipocytokines) can be defined as a group of more than 600 bioactive molecules made from adipose tissue that acts as paracrine and endocrine hormones. Adipokines are involved in maintaining varieties of processes such as, appetite and satiety, energy expenditure activity, endothelial function, blood pressure, hemostasis, adipogenesis, insulin sensitivity, energy metabolism in insulin-sensitive tissues, fat distribution and insulin secretion in pancreatic β-cells. Adipokines may contribute to reduce scar formation and improve cardiac function in coronary artery disease (CAD). Reperfusion therapy such as percutaneous coronary intervention (PCI) should be administered to all eligible patients with CAD symptom. However, our previous work showed that obese patients may benefit more from PCI. Thus, the aim of the present study was to investigate the efficacy and mechanism of adipokines cardiac protection for obese and non-obese patients with coronary artery disease (CAD).
Interventions
PROCEDUREPCI
percutaneous coronary intervention
Sponsors
Xijing Hospital
Study design
Observational model
CASE_CONTROL
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
20 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
coronary artery disease according to the WHO definition With or without percutaneous coronary intervention
Exclusion criteria
previous Coronary artery bypass grafting (CABG) cardiomyopathy atrial fibrillation or flutter previous heart surgery severe valvular heart disease disease of the hematopoietic system NYHA functional class IV heart failure at baseline severe renal, lung and liver disease cancer
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Number of patient death during the follow up period | 1 year |
Secondary
| Measure | Time frame |
|---|---|
| Left ventricular ejection fraction | 1 year |
| Number of target vessel revascularization | 1 year |
| Angina class according to the canadian cardiovascular society (CCS) classification | 1 year |
| Scores on the Seattle angina questionnaire | 1 year |
| six-min walk distance (6MWD) | 1 year |
Countries
China
Contacts
Primary ContactDongdong Sun, MD, PhD
Backup ContactWanrong Man, MD
Outcome results
None listed